5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Last Updated: Thursday, April 6, 2023
The estimated 5-year overall survival rate for patients with refractory large B-cell lymphoma who were treated with axicabtagene ciloleucel in the phase ZUMA-1 trial was 42.6%. No new treatment-related serious adverse events or deaths were observed during this longer follow-up.
Advertisement
News & Literature Highlights